The two serum markers sFlt1 and PlGF, especially the ratio of both, is generally used to stratify the individual risk of preeclampsia (PE) in symptomatic women in the context of the imbalance between angiogenic factors such as vascular endothelial growth factor (VEGF) or PlGF and anti-angiogenic factors like sFlt1 [4]. This evidence concerns the gene VEGFA and preeclampsia.